Answers are grounded in this paper and cite their sources.
The BM, AT and UC are feasible sources for harvesting equine MSCs, and their immunophenotypic and multipotency characteristics attained minimal criteria for defining MSCs. Due to the low expression of MHC-II by MSCs, all of the sources could be used in clinical trials involving allogeneic therapy in horses. However, the BM-MSCs and AT-MSCs showed fastest ''in vitro'' differentiation and AT-MSCs showed highest cell growth until third passage. These findings suggest that BM and AT may be preferable for cell banking purposes.
No takes yet. Share an insight, caveat, or question.
Barberini et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: